Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma

Basit Öğe Kaydı
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKalkan, Ziya
dc.contributor.authorTunç, Sezai
dc.contributor.authorİleri, Serdar
dc.contributor.authorOruç, Zeynep
dc.contributor.authorEbınc, Senar
dc.contributor.authorUrakçı, Zuhat
dc.date.accessioned2024-04-24T19:13:11Z
dc.date.available2024-04-24T19:13:11Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: The prognosis of metastatic malignant melanoma is poor. In this study, we aim to evaluate the response rates, PFS and OS times obtained with Nivolumab, Ipilimumab and Dabrafenib plus Trametinib in the treatment of advanced malignant melanoma, as well as the side effect profiles of these three agents. Methods: This study included 58 patients diagnosed with advanced malignant melanoma who received Nivolumab, Ipilimumab or Dabrafenib plus Trametinib therapy between January 2010 - March 2021 and had follow-up at our clinic. Response rates, survival times and side effects associated with each of the three treatment arms were evaluated. Nivolumab, Ipilimumab and Dabrafenib plus Trametinib were compared with regard to effectiveness and tolerability. Results: The Nivolumab, Ipilimumab and Dabrafenib plus Trametinib treatment arms, included 34 (58.6%), 13 (22.4%) and 11 (19%) patients, respectively. The comparison of Nivolumab, Ipilimumab and Dabrafenib plus Trametinib yielded, respectively; ORR (53%, 38.5%, 72.8%), mPFS (7 months, 3 months, 9 months) (p=0.57), mOS (12 months, 16 months, 15 months) (p=0.85). Conclusion: In this study that we conducted with real life data, we confirmed that Nivolumab, Ipilimumab and Dab rafenib plus Trametinib have different effectiveness adn manageable side effect profiles in the treatment of advanced malignant melanoma.en_US
dc.identifier.doi10.14744/ejmi.2022.79013
dc.identifier.endpage435en_US
dc.identifier.issn2602-3164
dc.identifier.issue4en_US
dc.identifier.startpage429en_US
dc.identifier.trdizinid1133753
dc.identifier.urihttps://doi.org/10.14744/ejmi.2022.79013
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1133753
dc.identifier.urihttps://hdl.handle.net/11468/28445
dc.identifier.volume6en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofEurasian Journal of Medical Investigation
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEvaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanomaen_US
dc.titleEvaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu